Selective estrogen receptor modulators (SERMs) / edited by Marietta Anthony, Barbara K. Dunn, and Sherry Sherman.

Format:

Book

Contributor:

Anthony, Marietta.

Dunn, Barbara K.

Sherman, Sherry.

Series:

Annals of the New York Academy of Sciences 0077-8923 ; v. 949.

Annals of the New York Academy of Sciences, 0077-8923 ; v. 949

Language:

English

Subjects (All):

Selective estrogen receptor modulators--Congresses.

Selective estrogen receptor modulators.

Selective Estrogen Receptor Modulators.

Medical Subjects:

Selective Estrogen Receptor Modulators.

Genre:

Conference papers and proceedings.

Physical Description:

xiii, 390 pages : illustrations (some color) ; 24 cm.

Place of Publication:

New York : New York Academy of Sciences, 2001.

Contents:

Part I. Basic Biology of SERMs

The Basic Biology of SERMs: Introduction / Ronald Margolis 1

Nuclear Receptors, Coregulators, Ligands, and Selective Receptor Modulators: Making Sense of the Patchwork Quilt / Neil J. McKenna, Bert W. O'Malley 3

Structure-Function Relationships in Estrogen Receptors and the Characterization of Novel Selective Estrogen Receptor Modulators with Unique Pharmacological Profiles / Benita S. Katzenellenbogen, Jun Sun, William R. Harrington, Dennis M. Kraichely, Deshanie Ganessunker, John A. Katzenellenbogen 6

Capitalizing on the Complexities of Estrogen Receptor Pharmacology in the Quest for the Perfect SERM / Donald P. McDonnell, Ching-yi Chang, John D. Norris 16

Developing Animal Models for Analyzing SERM Activity / Judith M.A. Emmen, Kenneth S. Korach 36

Androgen Receptor: Structural Domains and Functional Dynamics after Ligand-Receptor Interaction / Arun K. Roy, Rakesh K. Tyagi, Chung S. Song, Yan Lavrovsky, Soon C. Ahn, Tae-Sung Oh, Bandana Chatterjee 44

Tissue-Specific Estrogen Biosynthesis and Metabolism / Evan R. Simpson, Colin Clyne, Caroline Speed, Gary Rubin, Serdar Bulun 58

Part II. Cancer Treatment and Prevention

Cancer Treatment and Prevention: Introduction / Barbara K. Dunn, Barry Kramer 68

The Past, Present, and Future of Selective Estrogen Receptor Modulation / V. Craig Jordan 72

Use of SERMs for the Adjuvant Therapy of Early-Stage Breast Cancer / Antonio C. Wolff, Nancy E. Davidson 80

Breast Cancer Prevention with Selective Estrogen Receptor Modulators: A Perspective / Kathleen I. Pritchard 89

The Role of Tamoxifen in Breast Cancer Prevention: Issues Sparked by the NSABP Breast Cancer Prevention Trial (P-1) / Norman Wolmark, Barbara K. Dunn 99

The Royal Marsden Hospital (RMH) Trial: Key Points and Remaining Questions / Trevor J. Powles 109

The Italian Breast Cancer Prevention Trial with Tamoxifen: Findings and New Perspectives / Aliana Guerrieri-Gonzaga, Arianna Galli, Nicole Rotmensz, Andrea Decensi 113

A Brief Review of the International Breast Cancer Intervention Study (IBIS), the Other Current Breast Cancer Prevention Trials, and Proposals for Future Trials / J. Cuzick 123

The MORE Trial

Multiple Outcomes for Raloxifene Evaluation: Breast Cancer as a Secondary End Point

Implications for Prevention / Maura N. Dickler, Larry Norton 134

Quality of Life and Tamoxifen in a Breast Cancer Prevention Trial: A Summary of Findings from the NSABP P-1 Study / Richard Day 143

Part III. Cardiovascular Disease

Selective Estrogen Receptor Modulators and Cardiovascular Disease: Introduction / David J. Gordon 151

Cardiovascular Trials of Estrogen Replacement Therapy / David M. Herrington, Karen Potvin Klein 153

The Effects of Estrogen and Selective Estrogen Receptor Modulators on Cardiovascular Risk Factors / Brian W. Walsh 163

Selective Estrogen Receptor Modulator Effects on Serum Lipoproteins and Vascular Function in Postmenopausal Women and in Hypercholesterolemic Men / Arnon Blum, Richard O. Cannon, III 168

Effects of Estrogen and Selective Estrogen Receptor Modulators on Hemostasis and Inflammation: Potential Differences among Drugs / Mary Cushman 175

Rationale and Overview of the Raloxifene Use for the Heart (RUTH) Trial / Lori Mosca 181

Part IV. Osteoporosis

Prevention and Treatment of Osteoporosis: Introduction / Saralyn Mark, Jhumka Gupta 186

Preventing and Treating Osteoporosis: Strategies at the Millennium / Sherry Sherman 188

The Paradox of Small Changes in Bone Density and Reductions in Risk of Fracture with Raloxifene / Steven R. Cummings 198

Part IV. Cognitive Function

SERMs, Estrogen, and Cognitive Function: Introduction / Andrew A. Monjan 202

Effects of Hormone Replacement Therapy on Cognitive and Brain Aging / Susan M. Resnick, Pauline M. Maki 203

Estrogens, Selective Estrogen Receptor Modulators, and Dementia: What Is the Evidence? / Kristine Yaffe 215

Estrogen Replacement Therapy for the Potential Treatment or Prevention of Alzheimer's Disease / Marilyn M. Miller, Andrew A. Monjan, Neil S. Buckholtz 223

Part V. Reproductive and Related Endocrine Considerations

Reproductive and Related Endocrine Considerations: Introduction / Estella C. Parrott 235

The Effect of SERMs on the Endometrium / Steven R. Goldstein 237

Effect of Selective Estrogen Receptor Modulators on Reproductive Tissues Other Than Endometrium / Susan L. Hendrix, S. Gene McNeeley 243

The Effect of Selective Estrogen Receptor Modulators on Parameters of the Hypothalamic-Pituitary-Gonadal Axis / Leo Plouffe, Jr., Suresh Siddhanti 251

Part VI. Addressing the Benefit/Risk Ratio in Taking SERMs from Laboratory to Clinic

Translation of Basic Research

Finding the Perfect SERM: Introduction / Francis L. Bellino, Loretta Finnegan 259

What Would Be the Properties of an Ideal SERM? / Marietta Anthony, J. Koudy Williams, Barbara K. Dunn 261

Weighing the Benefits and Risks in Clinical Trials and Practice: Introduction / Worta McCaskill-Stevens 279

Benefit/Risk Assessment of SERM Therapy: Clinical Trial versus Clinical Practice Settings / Joseph P. Costantino 280

The Estimation and Use of Absolute Risk for Weighing the Risks and Benefits of Selective Estrogen Receptor Modulators for Preventing Breast Cancer / Mitchell H. Gail 286

SERMs, Ethnicity, and Clinical Trials: Opportunities and Challenges / Anne L. Taylor 292

Raloxifene: Risks and Benefits / Elizabeth Barrett-Connor 295

Defining Benefits and Risks for SERMs in Clinical Trials and Clinical Practice / Susan R. Johnson, Barbara K. Dunn, Marietta Anthony 304

Part VII. SERM Development in Industry, Academia, the NIH, and the FDA

Roles of Industry, Government, and Academia in SERM Development: Introduction / Marietta Anthony, Karen Johnson 315

Developing a SERM: Stringent Preclinical Selection Criteria Leading to an Acceptable Candidate (WAY-140424) for Clinical Evaluation / Barry S. Komm, C. Richard Lyttle 317

The Breast Cancer Continuum: Insights from the Tamoxifen Trials Impact Future Drug Development Strategies / Jerry P. Lewis 327

The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute: Industry Collaborations in New Agent Development / Sherry S. Ansher, Rami Scharf 333

FDA Review Practices and Priorities for Drugs Used in Cancer Treatment / Ken Kobayashi, Robert J. DeLap 341

Tamoxifen for the Reduction in the Incidence of Breast Cancer in Women at High Risk for Breast Cancer / Susan Flamm Honig 345

Negotiating Industry-Sponsored Clinical Trial Agreements: A View from the Trenches / Nikki J. Zapol 349

Conclusions: Considerations Regarding SERMs / Barbara K. Dunn, Marietta Anthony, Sherry Sherman, Joseph P. Costantino 352

Opportunites for Future Research / Sherry Sherman, Barbara K. Dunn 366

Everything You Wanted to Know about SERMs

Timeline of Key Events in SERM Development 377

Estrogen Receptor-Active Compounds, Estrogens, and SERMs, of Historical and Current Interest 381

Model of Estrogen Receptor (ER) Action 382

Action of SERMs in Target Tissues 383.

Notes:

"This volume is the result of the NIH Workshop on Selective Estrogen Receptor Modulators (SERMs) held April 26-28, 2000 in Bethesda, Maryland"--Contents p.

Includes bibliographical references and index.

ISBN:

1573313580

1573313599

OCLC:

48032562